Cogent Biosciences (COGT) News Today

Sofinnova Investments Inc. lifted its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 15.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,773,286 shares of the technology

Cogent Biosciences (NASDAQ:COGT) Trading Down 3.3%

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has received an average rating of "Moderate Buy" from the seven brokerages that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation t

Cogent Biosciences (NASDAQ:COGT) Shares Up 5.8%

Cogent Biosciences (NASDAQ:COGT) Trading Down 6.6%

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Stock analysts at Wedbush boosted their FY2027 EPS estimates for shares of Cogent Biosciences in a note issued to investors on Tuesday, September 3rd. Wedbush analyst D. Nierengarten now anticipates that the technology company will post earni

Robert W. Baird boosted their price objective on shares of Cogent Biosciences from $8.00 to $10.00 and gave the company a "neutral" rating in a research report on Thursday.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at HC Wainwright lifted their Q3 2024 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research report issued to clients and investors on Tuesday, September 3rd. HC Wainwright analyst R. Burns now ant

Wedbush reaffirmed a "neutral" rating and issued a $11.00 target price (up from $10.00) on shares of Cogent Biosciences in a report on Tuesday.

HC Wainwright cut their target price on shares of Cogent Biosciences from $19.00 to $17.00 and set a "buy" rating for the company in a report on Tuesday.

Panagora Asset Management Inc. reduced its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 19.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 246,333 shares of the technology company's stock after selling 60,912 shares d

Cogent Biosciences (NASDAQ:COGT) Trading 4.3% Higher

Hennion & Walsh Asset Management Inc. acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 127,712 shares of the tech

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have issued

Cogent Biosciences (NASDAQ:COGT) Stock Price Up 10.1%

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Investment analysts at Leerink Partnrs lifted their Q3 2024 earnings per share estimates for Cogent Biosciences in a research report issued to clients and investors on Tuesday, August 6th. Leerink Partnrs analyst A. Berens now forecasts that

Vanguard Group Inc. lifted its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 27.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,765,705 shares of the technology company'

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at Leerink Partnrs cut their FY2027 earnings per share estimates for shares of Cogent Biosciences in a research note issued on Tuesday, August 6th. Leerink Partnrs analyst A. Berens now anticipates that the technology company will po

Cogent Biosciences (NASDAQ:COGT - Get Free Report) released its quarterly earnings results on Tuesday. The technology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same quarter last year, the company posted ($0.59) earnings per share.

JPMorgan Chase & Co. reduced their price target on shares of Cogent Biosciences from $22.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday.

Needham & Company LLC reaffirmed a "buy" rating and issued a $18.00 target price on shares of Cogent Biosciences in a report on Wednesday.

Wedbush reissued a "neutral" rating and issued a $10.00 target price on shares of Cogent Biosciences in a report on Tuesday.

Cogent Biosciences (NASDAQ:COGT) Shares Down 3.8%

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 10,390,000 shares, a growth of 7.3% from the June 30th total of 9,680,000 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 8.5 days.

Janus Henderson Group PLC raised its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 12,785.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,099,357 shares of the tech

Kennedy Capital Management LLC grew its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 120.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 705,631 shares of the technology company's stock after buying an additional 385,315 shares during t

Cogent Biosciences (NASDAQ:COGT) Trading 7% Higher

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five hav

Cogent Biosciences (NASDAQ:COGT) Trading Down 4.9%

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy

Cogent Biosciences (NASDAQ:COGT) Stock Price Up 5.6%

Cogent Biosciences (NASDAQ:COGT) Trading Down 5.3%

Cogent Biosciences (NASDAQ:COGT) Stock Price Up 5.1%

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) saw a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 14,400,000 shares, an increase of 7.0% from the May 15th total of 13,460,000 shares. Based on an average trading volume of 1,400,000 shares, the short-interest ratio is presently 10.3 days.

Cogent Biosciences (NASDAQ:COGT) Shares Down 6.5%

Needham & Company LLC reaffirmed a "buy" rating and set a $18.00 price objective on shares of Cogent Biosciences in a research report on Monday.

Perceptive Advisors LLC cut its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 51.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,122,958 shares of the technology compan

Frazier Life Sciences Management L.P. lifted its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 32.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,995,267 shares of the technology company's stock a

Rafferty Asset Management LLC grew its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 50.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 288,671 shares of the technology company's stock after acq

Kynam Capital Management LP grew its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 164.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,854,766 shares of the technology company's stock after

Cogent Biosciences (NASDAQ:COGT) Trading Down 5.4%

New Leaf Venture Partners L.L.C. reduced its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 50.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 250,765 shares of the technology company's